Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-versus-Host Disease

Web Exclusives - FDA Approvals, Select Drug Profiles

On July 16, 2021, the FDA accelerated the approval of belumosudil (Rezurock; Kadmon Pharmaceuticals), an oral kinase inhibitor, for the treatment of patients aged ≥12 years with chronic graft-versus-host disease (GVHD) who have received ≥2 lines of systemic therapy. Belumosudil was granted a breakthrough therapy designation for this indication.

“Rezurock represents a new treatment paradigm for thousands of chronic GVHD patients, including those with difficult-to-treat manifestations like fibrosis,” said Corey Cutler, MD, MPH, FRCPC, Associate Professor of Medicine, Harvard Medical School, and Medical Director, Adult Stem Cell Transplantation Program, Dana-Farber Cancer Institute, Boston. “Rezurock has shown robust and durable responses across the spectrum of chronic GVHD, and is safe and well-tolerated.”

Belumosudil was approved based on the KD025-213 study, a randomized, open-label, multicenter dose-ranging clinical trial of 65 patients with chronic GVHD who received belumosudil 200 mg once daily. The main efficacy measure was overall response rate (ORR) through cycle 7 of day 1.

The ORR was 75% (95% confidence interval, 63%-85%), which included 6% complete responses and 69% partial responses. The median time to first response was 1.8 months. The median duration of response was 1.9 months. Among the patients who achieved a response, no death or new systemic therapy initiation occurred in 62% of the patients for at least 12 months since the response.

The most common (≥20%) adverse events were infections, asthenia, nausea, diarrhea, dyspnea, cough, edema, hemorrhage, abdominal pain, musculoskeletal pain, headache, phosphate decreased, gamma glutamyl transferase increased, lymphocytes decreased, and hypertension.

Related Items
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
Web Exclusives published on December 7, 2021 in FDA Approvals
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
Web Exclusives published on November 30, 2021 in FDA Approvals
Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease
Web Exclusives published on October 29, 2021 in FDA Approvals, Select Drug Profiles
Jakafi a New Treatment Option for Chronic Graft-versus-Host Disease
Web Exclusives published on October 29, 2021 in FDA Approvals, Select Drug Profiles
Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation
Loretta Fala
December 2021 Twelfth Annual Payers' Guide published on October 27, 2021 in FDA Approvals
Last modified: November 2, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.